Table 1.
Demographics, clinical and laboratory features of controls and RA patients at baseline and after 12-week treatment.
| Rheumatoid Arthritis (n = 19) |
EULAR Responders (n = 11) |
EULAR moderate/non-responders (n = 8) |
Controls (n = 14) |
||||
|---|---|---|---|---|---|---|---|
| Baseline | Baseline | 12 weeks | Baseline | 12 weeks | Baseline | ||
| Men/women, n | 4/15 | 2/9 | 2/6 | 5/9 | |||
| Age (mean ± SD, years) | 54.2 ± 16.0 | 47.9 ± 14.8 | 62.8 ± 14.1 | 39.0 ± 12.6 | |||
| Disease duration (mean ± SD, years) | 7.3 ± 7.4 | 6.0 ± 7.2 | 9.0 ± 7.6 | n/a | |||
| Disease activity | |||||||
| Tender joint count (28), n | 7.9 ± 5.3 | 7.3 ± 5.4 | 1.0 ± 1.8* | 8.8 ± 5.5 | 5.4 ± 4.7* | 0 | |
| Swollen joint count (28), n | 5.4 ± 4.0 | 3.9 ± 3.8 | 0.8 ± 1.5* | 7.5 ± 3.6 | 4.0 ± 3.2* | 0 | |
| ESR (mm/1st h) | 34 ± 23 | 33 ± 28 | 12 ± 15* | 36 ± 15 | 26 ± 7* | n/a | |
| CRP (mg/dl) | 1.7 ± 1.5 | 1.6 ± 1.9 | 0.3 ± 0.3* | 1.9 ± 0.9 | 0.9 ± 0.6* | n/a | |
| DAS28-ESR | 5.2 ± 1.2 | 5.0 ± 1.3 | 2.0 ± 0.8* | 5.5 ± 1.1 | 4.5 ± 1.2* | n/a | |
| Auto-antibodies | |||||||
| RF positivity, n (%) | 11 (57.9) | 6 (54.5) | 5 (62.5) | n/a | |||
| anti-CCP positivity, n (%) | 12 (63.2) | 7 (63.6) | 5 (62.5) | n/a | |||
| Therapy | |||||||
| csDMARDs, n (%) | 5 (26.3) | 3 (27.3) | 6 (54.5) | 2 (25.0) | 4 (50.0) | 0 | |
| corticosteroids, n (%) | 6 (31.6) | 3 (27.3) | 5 (45.5) | 3 (37.5) | 4 (50.0) | 0 | |
| anti-TNF, n (%) | 0 (0.0) | 0 (0.0) | 6 (54.5) | 0 (0.0) | 5 (62.5) | 0 | |
| anti-IL-1, n (%) | 0 (0.0) | 0 (0.0) | 2 (18.2) | 0 (0.0) | 0 (0.0) | 0 | |
| anti-CD20, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (12.5) | 0 | |
ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DAS: disease activity score; RF: rheumatoid factor; anti-CCP: anti-cyclic citrullinated peptide; csDMARDS: conventional synthetic disease-modifying antirheumatic drugs(methotrexate, leflunomide); TNF: tumor necrosis factor; IL-1: interleukin 1; *P < 0.05 compared to baseline.